AstraZeneca moved to bolster the company’s COVID-19 portfolio of antibodies on May 17 with a $157 million licensing deal for experimental therapies developed by newly launched biotech RQ Bio.
Shanghai set out plans on May 16 for the end of a painful COVID-19 lockdown that has lasted more than six weeks, heavily bruising China’s economy, and for the return of more normal life from June 1.
Bristol Myers Squibb shared the news that the company’s Phase III clinical trial investigating the safety and efficacy of Opdivo and Yervoy combination therapy (NCT03036098) in patients with metastatic urothelial carcinoma failed to meet the predetermined primary endpoint. A posthoc analysis was shared by Synairgen suggesting that, despite SNG001 failing to meet the primary endpoint of patient recovery and subsequent hospital discharge in a Phase III study for patients hospitalized with COVID-19 who required supplemental oxygen treatment, they may benefit from receiving the treatment.
The United States will share technologies used to make COVID-19 vaccines through the World Health Organization and is working to expand rapid testing and antiviral treatments for hard-to-reach populations, President Joe Biden said on May 12.
President Joe Biden on May 12 commemorated the death of 1 million people in the United States from COVID-19, marking what he called “a tragic milestone” and urging Americans to “remain vigilant” amid the ongoing pandemic.
Building on the success of its COVID-19 mRNA vaccine, Moderna, Inc. is partnering with the nonprofit scientific research organization IAVI to develop treatments and vaccines against global health threats.
The U.S. Food and Drug administration granted priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalized adults.
Outside advisers to the U.S. Food and Drug Administration on Oct. 15 unanimously recommended the regulatory agency authorize a second shot of Johnson & Johnson’s Covid-19 vaccine for all recipients of the one-dose inoculation.
AstraZeneca requested emergency use authorization from U.S. regulators for the company’s new treatment to prevent Covid-19 for people who respond poorly to vaccines because of a weakened immune system.
As Merck & Co. and Pfizer Inc. prepare to report clinical trial results for experimental Covid-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own.